Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health. Our team works collaboratively and relentlessly to advance our therapies with the goal of improving the lives of patients, their families, and their caregivers. The Radius portfolio consists of commercial and clinical development assets that include mid to late-stage drug candidates.
We are dedicated to serving those patients suffering from bone loss like the 8.9 million osteoporotic fractures that occur annually worldwide1. In 2017, we launched our first commercial product in the U.S., TYMLOS® (abaloparatide injection), for the treatment of postmenopausal women with osteoporosis at high risk for fracture. In 2022, Radius announced the FDA approval to expand TYMLOS® (abaloparatide injection) as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.